Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Extramedullary Relapses after Allogeneic Stem Cell Transplant (allo-SCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Hiroaki Shimizu, MD PhD, Takuma Ishizaki, MD PhD, Nahoko Hatsumi, MD, Satoru Takada, MD, Akihiko Yokohama, MD PhD, Takayuki Saitoh, MD PhD, Toru Sakura, PhD MD, Hiroshi Handa, MD PhD

Blood (2019) 134 (Supplement_1): 5690.

https://doi.org/10.1182/blood-2019-130590

Published: 2019

Journal Articles

Clinical Significance of Clonal Cytogenetic Heterogeneity (CCH) at Diagnosis in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Hiroaki Shimizu, MD PhD, Nahoko Hatsumi, MD, Satoru Takada, MD, Takuma Ishizaki, MD PhD, Akihiko Yokohama, MD PhD, Takayuki Saitoh, MD PhD, Toru Sakura, PhD MD, Hiroshi Handa, MD PhD

Blood (2018) 132 (Supplement 1): 2820.

https://doi.org/10.1182/blood-2018-99-118462

Published: 2018

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)

Hiroaki Shimizu, MD PhD, Satoru Takada, MD, Nahoko Hatsumi, MD, Akihiko Yokohama, MD PhD, Takayuki Saitoh, MD PhDProf, Toru Sakura, PhD MD, Hiroshi Handa, MD PhDChief Division

Blood (2017) 130 (Supplement 1): 2716.

https://doi.org/10.1182/blood.V130.Suppl_1.2716.2716

Published: 2017

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Acute Myeloid Leukemia (AML) Patients

Hiroaki Shimizu, MDPhD, Akihiko Yokohama, MD PhD, Nahoko Hatsumi, MD, Satoru Takada, MD, Takayuki Saitoh, MD, PhD, Hiroshi Handa, MD, Toru Sakura, MD PhD, Yoshihisa Nojima, MD PhD

Blood (2014) 124 (21): 3673.

https://doi.org/10.1182/blood.V124.21.3673.3673

Published: 2014

Journal Articles

Gentuzumab Ozogamicin (GO:Mylotarg) Monotherapy for Relapsed AML after Hematopoietic Stem Cell Transplantation: from Morphological Target to Molecular Target.

Shuichi Miyawaki, MD, Nahoko Hatsumi, MD, Takumi Hoshino, MD, Toshihide Kawamura, MD, Satoru Takada, MD, Tohru Sakura, MD

Blood (2007) 110 (11): 5026.

https://doi.org/10.1182/blood.V110.11.5026.5026

Published: 2007

NARROW

Extramedullary Relapses after Allogeneic Stem Cell Transplant (allo-SCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Clinical Significance of Clonal Cytogenetic Heterogeneity (CCH) at Diagnosis in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Acute Myeloid Leukemia (AML) Patients

Gentuzumab Ozogamicin (GO:Mylotarg) Monotherapy for Relapsed AML after Hematopoietic Stem Cell Transplantation: from Morphological Target to Molecular Target.

Email alerts

ASH Publications

American Society of Hematology

Extramedullary Relapses after Allogeneic Stem Cell Transplant (allo-SCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Clinical Significance of Clonal Cytogenetic Heterogeneity (CCH) at Diagnosis in Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Acute Myeloid Leukemia (AML) Patients

Gentuzumab Ozogamicin (GO:Mylotarg) Monotherapy for Relapsed AML after Hematopoietic Stem Cell Transplantation: from Morphological Target to Molecular Target.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only